

## Retrospective Study

**Serotonin type 3 receptor subunit gene polymorphisms associated with psychosomatic symptoms in irritable bowel syndrome: A multicenter retrospective study**

Sabrina Berens, Yuanjun Dong, Nikola Fritz, Jutta Walstab, Mauro D'Amato, Tenghao Zheng, Verena Wahl, Felix Boekstegers, Justo Lorenzo Bermejo, Cristina Martinez, Stefanie Schmitteckert, Egbert Clevers, Felicitas Engel, Annika Gauss, Wolfgang Herzog, Robin Spiller, Miriam Goebel-Stengel, Hubert Mönnikes, Viola Andresen, Frieling Thomas, Jutta Keller, Christian Pehl, Christoph Stein-Thöringer, Gerard Clarke, Timothy G Dinan, Eamonn M Quigley, Gregory Sayuk, Magnus Simrén, Jonas Tesarz, Gudrun Rappold, Lukas van Oudenhove, Rainer Schaefer, Beate Niesler

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): A  
Grade B (Very good): 0  
Grade C (Good): 0  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** Yin ZT, China

**Received:** July 19, 2021

**Peer-review started:** July 19, 2021

**First decision:** August 9, 2021

**Revised:** August 21, 2021

**Accepted:** April 22, 2022

**Article in press:** April 22, 2022

**Published online:** June 7, 2022



**Sabrina Berens**, Department of General Internal Medicine and Psychosomatics, University Hospital Heidelberg, Heidelberg 69120, Germany

**Yuanjun Dong, Nikola Fritz, Verena Wahl, Cristina Martinez, Stefanie Schmitteckert, Gudrun Rappold**, Department of Human Molecular Genetics, Institute of Human Genetics, University of Heidelberg, Heidelberg 69120, Germany

**Yuanjun Dong, Felicitas Engel, Jonas Tesarz, Rainer Schaefer**, Department of General Internal Medicine and Psychosomatics, Internal Medicine II, University Hospital Heidelberg, Heidelberg 69120, Germany

**Jutta Walstab**, Department of Human Molecular Genetics, University of Heidelberg, Heidelberg 69120, Germany

**Mauro D'Amato**, Gastrointestinal Genetics Lab, CIC bioGUNE - BRTA, Derio 48160, Spain

**Mauro D'Amato**, IKERBASQUE, Basque Foundation for Science, Bilbao 48001, Spain

**Mauro D'Amato, Tenghao Zheng**, Unit of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm 17177, Sweden

**Felix Boekstegers, Justo Lorenzo Bermejo**, Institute of Medical Biometry and Informatics, Heidelberg University, Heidelberg 69120, Germany

**Cristina Martinez**, Lleida Institute for Biomedical Research Dr. Pifarré Foundation (IRBLleida), Av. Alcalde Rovira Roure, Lleida 25198, Spain

**Egbert Clevers**, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven 3000, Belgium

**Annika Gauss**, Department of Gastroenterology, Infectious Diseases and Intoxications, University of Heidelberg, Heidelberg 69120, Germany

**Wolfgang Herzog**, Department of General Internal Medicine and Psychosomatics, Heidelberg University, Heidelberg 69120, Germany

**Robin Spiller**, Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham NG7 2QL, United Kingdom

**Miriam Goebel-Stengel**, Helios Klinikum Rottweil, Rottweil 78628, Germany

**Hubert Mönnikes**, Department of Medicine, Institute of Neurogastroenterology (H.M.), Martin-Luther-Hospital, Belin 14193, Germany

**Viola Andresen**, Israelitisches Krankenhaus in Hamburg, Hamburg 22297, Germany

**Frieling Thomas**, Internal Medicine II, Helios Klinikum Krefeld, Krefeld 47805, Germany

**Jutta Keller**, Israelitisches Krankenhaus Hamburg, Hamburg 22297, Germany

**Christian Pehl**, Krankenhaus Vilsbiburg, Vilsbiburg 84137, Germany

**Christoph Stein-Thöringer**, Division of Microbiome and Cancer, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany

**Gerard Clarke, Timothy G Dinan**, Department of Psychiatry and Neurobehavioral Science, University College Cork, Cork T23, Ireland

**Eamonn M Quigley**, Medicine in Digestive Disorders, Department of Medicine, Lynda K. and David M. Underwood Center for Digestive Disorders, Houston Methodist, Houston, TX 77030, United States

**Gregory Sayuk**, Division of Gastroenterology, Washington University School of Medicine, Department of Psychiatry, School of Medicine, John Cochran Veteran Affairs Medical Center, St. Louis, MO 63110, United States

**Magnus Simrén**, Department of Internal Medicine, Section of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg SE-41685, Sweden

**Gudrun Rappold, Beate Niesler**, Interdisciplinary Center for Neurosciences (IZN), University of Heidelberg, Heidelberg 69120, Germany

**Lukas van Oudenhove**, Cognitive and Affective Neuroscience Lab, Department of Psychological and Brain Sciences, Dartmouth College, Hanover, NH 03748, United States

**Lukas van Oudenhove**, Laboratory for Brain-Gut Axis Studies, Translational Research Center for Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism, and Ageing, KU Leuven, Leuven 3000, Belgium

**Rainer Schaefer**, Department of Psychosomatic Medicine, Division of Internal Medicine, University Hospital Basel, Basel CH-4031, Switzerland

**Beate Niesler**, Department of Human Molecular Genetics, Heidelberg University, Heidelberg 69120, Germany

**Corresponding author:** Beate Niesler, PhD, Academic Fellow, Full Professor, Senior Scientist, Department of Human Molecular Genetics, Heidelberg University, Neuenheimer Feld 366, Heidelberg 69120, Germany.

[beate.niesler@med.uni-heidelberg.de](mailto:beate.niesler@med.uni-heidelberg.de)

## Abstract

### BACKGROUND

Single-nucleotide polymorphisms (SNPs) of the serotonin type 3 receptor subunit (*HTR3*) genes have been associated with psychosomatic symptoms, but it is not clear whether these associations exist in irritable bowel syndrome (IBS).

### AIM

To assess the association of *HTR3* polymorphisms with depressive, anxiety, and somatization symptoms in individuals with IBS.

### METHODS

In this retrospective study, 623 participants with IBS were recruited from five specialty centers in Germany, Sweden, the United States, the United Kingdom, and Ireland. Depressive, anxiety, and

somatization symptoms and sociodemographic characteristics were collected. Four functional SNPs – *HTR3A* c.-42C>T, *HTR3B* c.386A>C, *HTR3C* c.489C>A, and *HTR3E* c.\*76G>A – were genotyped and analyzed using the dominant and recessive models. We also performed separate analyses for sex and IBS subtypes. SNP scores were calculated as the number of minor alleles of the SNPs above. The impact of *HTR3C* c.489C>A was tested by radioligand-binding and calcium influx assays.

## RESULTS

Depressive and anxiety symptoms significantly worsened with increasing numbers of minor *HTR3C* c.489C>A alleles in the dominant model ( $F_{\text{depressive}} = 7.475$ ,  $P_{\text{depressive}} = 0.006$ ;  $F_{\text{anxiety}} = 6.535$ ,  $P_{\text{anxiety}} = 0.011$ ). A higher SNP score (range 0-6) was linked to a worsened depressive symptoms score ( $F = 7.710$ ,  $P\text{-linear trend} = 0.006$ ) in IBS. The potential relevance of the *HTR3C* SNP was corroborated, showing changes in the expression level of 5-HT<sub>3</sub>AC variant receptors.

## CONCLUSION

We have provided the first evidence that *HTR3C* c.489C>A is involved in depressive and anxiety symptoms in individuals with IBS. The SNP score indicated that an increasing number of minor alleles is linked to the worsening of depressive symptoms in IBS.

**Key Words:** Irritable bowel syndrome; 5-HT<sub>3</sub> receptor subunit gene polymorphisms; Single-nucleotide polymorphism score; Depression; Anxiety; Somatization

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Bringing together high quality data as well as methodological expertise, our results show that: In the dominant model, *HTR3C* c.489C>A was correlated with depressive and anxiety symptoms in irritable bowel syndrome (IBS); a higher number of minor alleles, which was computed by combining the individual SNP status of *HTR3A* c.-42C>T, *HTR3B* c.386A>C, *HTR3C* c.489C>A, and *HTR3E* c.\*76G>A, was linked to more severe depressive symptoms in IBS; and the potential relevance of the *HTR3C* SNP was corroborated in functional assays showing changes in the expression level of 5-HT<sub>3</sub>AC variant receptors. These results will contribute towards standardization and harmonization of genetic research strategies in IBS.

**Citation:** Berens S, Dong Y, Fritz N, Walstab J, D'Amato M, Zheng T, Wahl V, Boekstegers F, Bermejo JL, Martinez C, Schmitteckert S, Clevers E, Engel F, Gauss A, Herzog W, Spiller R, Goebel-Stengel M, Mönnikes H, Andresen V, Thomas F, Keller J, Pehl C, Stein-Thöringer C, Clarke G, Dinan TG, Quigley EM, Sayuk G, Simrén M, Tesarz J, Rappold G, van Oudenhove L, Schaefer R, Niesler B. Serotonin type 3 receptor subunit gene polymorphisms associated with psychosomatic symptoms in irritable bowel syndrome: A multicenter retrospective study. *World J Gastroenterol* 2022; 28(21): 2334-2349

**URL:** <https://www.wjgnet.com/1007-9327/full/v28/i21/2334.htm>

**DOI:** <https://dx.doi.org/10.3748/wjg.v28.i21.2334>

## INTRODUCTION

Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal (GI) disorder characterized by abdominal pain and altered bowel habits[1-4]. The pathophysiology of IBS has not entirely been resolved, but is understood to be biopsychosocial and affected by an impaired function of the central and enteric nervous systems and their crosstalk *via* the brain-gut axis[5,6]. IBS patients often present with increased comorbid depressive and anxiety symptoms[7-11], highlighting the complex relationship between visceral sensitivity and subjective psychological perceptions[12,13]. Nevertheless, about 50% of IBS patients report GI symptoms but show no comorbid affective symptoms[14].

There is evidence that disturbances of the serotonergic system are important in GI disorders such as IBS and in mental disorders, both of which interact *via* the brain-gut axis[15,16]. The serotonin type 3 receptors (5-HT<sub>3</sub>R) modulate key functions in the GI tract[17,18]. In line with such functions, 5-HT<sub>3</sub>R antagonists are beneficial in the treatment of diarrhea-predominant IBS (IBS-D)[19-22]. 5-HT<sub>3</sub>Rs are also involved in emotional processing, mood regulation, and visceral perception and have been associated with depressive and anxiety symptoms that represent comorbid phenotypes in IBS[23]. Single-nucleotide polymorphisms (SNPs) in the 5-HT<sub>3</sub>R subunit genes (*HTR3*), namely *HTR3A* c.-42C>T (rs1062613), *HTR3B* c.386A>C (rs1176744), *HTR3C* c.489C>A (rs6766410), and *HTR3E* c.\*76G>A

(rs56109847), are associated with IBS according to studies investigating the effects of sex or IBS subtypes [12,24-30]. However, whether *HTR3* polymorphisms are associated with IBS and comorbid depressive and anxiety symptoms has not been determined because existing studies have missing phenotypic data on comorbidities and small sample sizes. These studies had case-control designs and investigated associations between these polymorphisms in individuals with IBS phenotypes or mental behavioral conditions and controls rather than combining genetic data with specific psychosocial characteristics of IBS patients.

This multicenter observational study focused on a large IBS patient cohort comprising 768 participants from centers in Germany, Sweden, the United States, the United Kingdom, and Ireland with the aim of meeting three objectives: (1) To explore the associations between functional *HTR3* polymorphisms and psychosomatic burden (*i.e.*, depressive, anxiety, and somatization symptoms) within an IBS population; (2) To investigate the impact of the *HTR3* SNP score (computed as the number of minor alleles) on psychosomatic burden, based on our hypothesis that the observed number of minor alleles was associated with specific mental characteristics in IBS patients; and (3) To perform a functional analysis of variant 5-HT<sub>3</sub>AC receptors.

## MATERIALS AND METHODS

### Subjects

The study population was pooled from five different tertiary care expert centers. German participants were recruited from the Specialty Clinic for Functional GI Disorders at the Department of General Internal Medicine and Psychosomatics of Heidelberg University Hospital[31] and from our clinical partners in the IBS-Net in Hamburg, Krefeld, Berlin, Vilsbiburg, and Munich ([www.ibs.uni-hd.de](http://www.ibs.uni-hd.de)). Swedish participants were recruited at the specialized unit for patients with functional GI disorders at Sahlgrenska University Hospital in Gothenburg. United States participants were recruited at Washington University, Barnes-Jewish Hospital in St. Louis, Missouri. United Kingdom participants were recruited at the Nottingham Digestive Diseases Center and participants from Ireland from a specialty clinic at Cork University Hospital. Participant recruitment is shown in [Figure 1](#).

Written informed consent was obtained from all participants and the experiments were in accordance with the principles of the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. All studies were approved by the following local Ethics Committees: Heidelberg, Germany: Ethical Committee, Medical Faculty of the Heidelberg University Hospital (S067/2010); Cork, Ireland: Clinical Research Ethics Committee (APC024); Gothenburg, Sweden: Regional Ethical Review Board in Gothenburg (S489-02 and 731-09); Nottingham, United Kingdom: registered at clinical trial [clinicaltrials.gov](http://clinicaltrials.gov) (identifier NCT00745004) and approved by Nottingham Research Ethics Committee 2 (REC reference number 08/H0408/134)[21]; and St-Louis, United States: Washington University St. Louis, Human Research Protection Office (IRB ID #: 201103220).

### Inclusion/exclusion criteria

Only patients diagnosed with IBS according to the ROME III criteria were included in the analysis. All participants were of Caucasian ancestry and had comparable population stratification. Patients under 18 years of age or without SNP test results were excluded.


### Genotyping

Genomic DNA was isolated from IBS patient blood samples using ethylenediaminetetraacetic acid according to standard protocols[32]. Four polymorphic *HTR3* loci, namely *HTR3A* c.-42C>T (rs1062613), *HTR3B* c.386A>C (rs1176744), *HTR3C* c.489C>A (rs6766410), and *HTR3E* c.\*76G>A (rs56109847) were selected as target SNPs for this study. The corresponding primers were designed and synthesized using AssayDesigner 3.1 software. Genotyping was performed at the Department of Human Molecular Genetics at Heidelberg University Hospital using the KASPar<sup>®</sup> SNP Genotyping System (KBiosciences, Ltd, Hoddesdon, United Kingdom). To analyze *HTR3* SNPs, the fluorescence plate reader of the 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, California, United States) was used as recommended. About 10% of the samples were repeat tested to ensure genotyping accuracy.

### Data collection

In addition to sociodemographic characteristics and IBS diagnosis, we also collected data on depressive, anxiety, and somatization symptoms[33] and genetic markers of the serotonergic system.

**IBS diagnosis:** The diagnostic classification of IBS was based on the Scoring Algorithm for Rome III Diagnostic Questionnaire for Adult Functional GI Disorders (SA for Rome III-DQ)[34,35] in all five centers. Percentages of the different IBS subtypes, *i.e.*, constipation-predominant IBS, IBS-D, IBS with mixed bowel habits, and unclassified IBS, were also calculated.



**Figure 1 Recruitment strategy.** IBS: Irritable bowel syndrome.

**Depressive symptoms:** The nine-item depression module from the Patient Health Questionnaire (PHQ-9)[36,37] was used to measure depressive symptoms in the German cohort. The Hospital Anxiety and Depression Scale depression subscale[38] was used to identify depressive symptoms in participants from Sweden, the United Kingdom, and Ireland and the Beck Depression Inventory[39] was used to measure the severity of depressive symptoms in United States participants.

**Anxiety symptoms:** In the German cohort, symptoms of generalized anxiety were assessed using the brief measurement for generalized anxiety disorder (GAD-7)[40]. In the cohorts from Sweden, the United Kingdom, and Ireland, the HADS anxiety subscale was used to identify anxiety symptoms. The Beck Anxiety Inventory[41] was used to assess anxiety in the United States cohort.

**Somatization symptoms:** In the cohorts from Germany, Sweden, and the United States, the 15-item somatization module from the PHQ-15[42] was used to identify somatization symptoms.

**Genetic markers of the serotonergic system:** The four functional SNPs *HTR3A* c.-42C>T (rs1062613), *HTR3B* c.386A>C (rs1176744), *HTR3C* c.489C>A (rs6766410), and *HTR3E* c.\*76G>A (rs56109847) were selected for validation based on previous reports as outlined above[25].

#### **Ligand binding and calcium influx assays**

These procedures are described in the [Supplementary material](#).

#### **Statistical analysis**

All statistical procedures were carried out using IBM SPSS Statistics 22.0 for Windows. Variables with a skewed distribution were log-transformed prior to further analysis. If different measurements had been collected in the five centers, *z* values were calculated to enable pooling. The Hardy-Weinberg equilibrium (HWE) of genotype frequency distribution was tested using SHEsis[43]. Genome-wide SNP data were generated by the Bellygenes team of D'Amato M using the Illumina Global Screening array and platform[44,45]. We used the multidimensional scaling approach to correct for population stratification in PLINK[46]. Following the guidance provided at [https://github.com/MareesAT/GWA\\_tutorial/](https://github.com/MareesAT/GWA_tutorial/), our data were anchored by data of the 1000 Genomes project (<http://www.1000genomes.org/>). The 10 main components were used as covariates in the association tests to correct for population stratification[46] and exclude outliers. Polymorphisms were analyzed separately using the dominant and the recessive models. Also, stratified analyses based on sex and IBS subtypes were carried out. ANOVA was used to analyze group differences and to check for linear trends in depressive, anxiety, and somatization symptoms. For the independent variable, a SNP score was computed based on the number of minor alleles (*i.e.*, continuous from 0 to 8 for the four SNPs). Based on the first human *HTR3* locus-specific variant database ([www.htr3.uni-hd.de](http://www.htr3.uni-hd.de))[25], scoring criteria were as follows: major allele homozygous variant gene = 0; heterozygous variant gene = 1; and minor allele homozygous variant gene = 2 (for details see [Table 1](#)). Statistical comparisons were made between the two groups using the  $\chi^2$  test or Fisher's exact test for frequencies and *t* tests or Mann-Whitney *U* tests for metric

**Table 1 Strategy for computing the single-nucleotide polymorphism score**

	Major allele homozygous genotype	Heterozygous variant genotype	Minor allele homozygous genotype
<i>HTR3A</i> c.-42C>T (rs1062613)	CC	CT	TT
<i>HTR3B</i> c.386A>C (rs1176744)	AA	AC	CC
<i>HTR3C</i> c.489C>A (rs6766410)	CC	CA	AA
<i>HTR3E</i> c.*76G>A (rs56109847)	GG	GA	AA

variables. Normal distribution and variance homogeneity were checked as conditions. Statistical tests were two-sided based on an alpha error of 0.05%. All analyses were explorative and not confirmatory. False discovery rates (FDRs) were calculated based on overall *P* values using the Benjamini-Hochberg method[47]. Significant values that were no longer significant after FDR multiple testing correction were named “nominally significant”.

## RESULTS

### **Sociodemographic and symptomatic characteristics**

In total, 623 participants from five independent expert centers were included in this study (45.1% from Germany, 18.3% from Sweden, 19.6% from the United States, 12.4% from the United Kingdom, and 4.7% from Ireland). We excluded 76 Swedish participants who did not meet the population stratification criteria (Supplementary Figure 1). Participants from the United Kingdom and Ireland were excluded from the main analysis because the sample size was small. Table 2 presents the sociodemographic characteristics, IBS subtypes, and psychosomatic symptoms of the included participants. Participants had a mean ± SD age of 41.7 ± 16.1 years and 69.5% were female. Overall, IBS patients showed minimal to mild levels of depressive and anxiety symptoms, moderate levels of IBS symptoms, and moderate levels of somatization symptoms.

### **HTR3 SNP genotypes and allele frequencies**

Genotype and allele frequencies of the functional *HTR3A* c.-42C>T, *HTR3B* c.386A>C, *HTR3C* c.489C>A, and *HTR3E* c.\*76G>A polymorphisms were calculated. No significant differences in genotype frequency were observed between sexes or IBS subtypes. For *HTR3A* c.-42C>T, the frequency of the minor *T* allele was 21.5%; for *HTR3B* c.386A>C, the frequency of the minor *C* allele was 29.6%; for *HTR3C* c.489C>A, the frequency of the minor *A* allele was 41.6%; and for *HTR3E* c.\*76G>A, the frequency of minor *A* allele was 6.1%. The genotypic distribution of the four polymorphic loci of rs1062613, rs1176744, rs6766410, and rs56109847 were in accordance with HWE (all *P* > 0.05). The results are shown in Supplementary Tables 1-3.

### **HTR3 SNP analysis using the dominant and the recessive model**

*HTR3* SNPs were separately analyzed using the dominant model and the recessive model stratified for sex and IBS subtypes. Depressive and anxiety symptoms worsened significantly with increasing numbers of minor alleles of *HTR3C* c.489C>A in the dominant model ( $F_{\text{depressive}} = 7.475$ ,  $P_{\text{depressive}} = 0.006$ ;  $F_{\text{anxiety}} = 6.535$ ,  $P_{\text{anxiety}} = 0.011$ ). This seemed to be driven by female sex ( $F_{\text{depressive}} = 7.040$ ,  $P_{\text{depressive}} = 0.008$ ;  $F_{\text{anxiety}} = 7.550$ ,  $P_{\text{anxiety}} = 0.006$ ) and IBS-D ( $F_{\text{depressive}} = 5.670$ ,  $P_{\text{depressive}} = 0.018$ ;  $F_{\text{anxiety}} = 13.444$ ,  $P_{\text{anxiety}} < 0.001$ ). The same trend was also found for *HTR3A* c.-42C>T in male participants with depressive symptoms in the dominant model ( $F_{\text{depressive}} = 4.149$ ,  $P_{\text{depressive}} = 0.043$ ). For the recessive model, depressive and somatization symptoms worsened with increasing numbers of minor alleles of *HTR3C* c.489C>A ( $F_{\text{depressive}} = 6.190$ ,  $P_{\text{depressive}} = 0.014$ ) and *HTR3B* c.386A>C ( $F_{\text{depressive}} = 6.482$ ,  $P_{\text{depressive}} = 0.011$ ), respectively in IBS-D participants. *F* values from the ANOVA are shown in Table 3. As mentioned above, the analyses of participants from the United Kingdom and Ireland are presented separately in the Supplementary Table 4.

### **Effect of SNP score on psychosomatic symptoms**

SNP scores ranged from 0 to 6; 37.1% had one or zero minor alleles of the analyzed *HTR3* SNPs and 30.8% had three or more minor alleles of the analyzed *HTR3* SNPs. No significant differences in SNP scores were observed between sexes ( $F = 3.550$ ,  $P = 0.060$ ) or IBS subtypes ( $F = 1.485$ ,  $P = 0.227$ ). ANOVAs were conducted and linear trends were checked to analyze the effect of SNP scores on depressive, anxiety, and somatization symptoms. Overall, an increasing number of minor alleles was linked to worsening depressive symptoms ( $F = 7.710$ ,  $P_{\text{linear trend}} = 0.006$ ). However, material trends did not reveal a link between more minor alleles and worsening anxiety or somatization symptoms. By stratifying analyses for sex, an increasing number of minor alleles was linked to worsened depressive

**Table 2 Sociodemographic and symptomatic characteristics of the study participants**

	Total	Centers				
		Germany	Sweden	United States	United Kingdom	Ireland
<i>n</i>	100.0 (623)	45.1 (281)	18.3 (114)	19.6 (122)	12.4 (77)	4.7 (29)
Age	41.7 ± 16.1 (18, 91)	40.7 ± 16.4 (18, 88)	33.7 ± 11.8 (18, 60)	54.9 ± 14.6 (25, 91)	40.8 ± 11.6 (18, 70)	30.3 ± 8.6 (19, 51)
Sex						
Female	69.5 (433)	63.3 (178)	69.3 (79)	77.9 (95)	72.7 (56)	86.2 (25)
IBS subtypes						
IBS-C	14.1 (87)	8.9 (25)	12.3 (14)	36.7 (44)	0	13.8 (4)
IBS-D	41.7 (258)	43.4 (122)	19.6 (22)	28.3 (34)	100.0 (77)	10.3 (3)
IBS-M	42.5 (263)	45.6 (128)	67.0 (75)	31.7 (38)	0	75.9 (22)
IBS-U <sup>1</sup>	1.8 (11)	2.1 (6)	0.9 (1)	3.3 (4)	0	0
Depressive symptoms	-	9.4 ± 5.9 <sup>2</sup>	5.2 ± 3.5 <sup>4</sup>	13.2 ± 9.6 <sup>5</sup>	5.9 ± 4.0 <sup>4</sup>	4.3 ± 3.2 <sup>4</sup>
Anxiety symptoms	-	7.7 ± 4.8 <sup>3</sup>	8.3 ± 4.5 <sup>4</sup>	14.6 ± 9.7 <sup>6</sup>	9.6 ± 4.6 <sup>4</sup>	7.8 ± 4.5 <sup>4</sup>
Symptom severity	-	280.3 ± 90.7 <sup>7</sup>	297.3 ± 100.5 <sup>7</sup>	43.2 ± 16.2 <sup>8</sup>	-	-
Somatization symptoms <sup>9</sup>	14.8±6.3	16.2 ± 7.3	13.3 ± 4.7	13.8 ± 5.0	-	-

Sample size, sex, IBS subtypes, and severity of depressive and anxiety symptoms are presented as % (*n*). Age is presented as mean ± SD (range). Scores of depressive and anxiety symptoms are presented as mean ± SD.

<sup>1</sup>Was not included in the later analysis because of the small sample size.

<sup>2</sup>Evaluated by the nine-item depression module from the Patient Health Questionnaire.

<sup>3</sup>Evaluated by the brief measurement for generalized anxiety disorder.

<sup>4</sup>Evaluated by Hospital Anxiety and Depression Scale.

<sup>5</sup>Evaluated by Beck Depression Inventory.

<sup>6</sup>Evaluated by Beck Anxiety Inventory.

<sup>7</sup>Evaluated by irritable bowel syndrome (IBS) symptom severity scale.

<sup>8</sup>Evaluated by the gastrointestinal symptom rating scale for IBS.

<sup>9</sup>Evaluated by the somatization module for the Patient Health Questionnaire.

IBS: Irritable bowel syndrome; IBS-C: Constipation-predominant IBS; IBS-D: Diarrhea-predominant IBS; IBS-M: IBS with mixed bowel habits; IBS-U: Unclassified IBS.

symptoms in female participants ( $F = 5.770$ ,  $P$ -linear trend = 0.017). There was no significant association between SNP score and depressive, anxiety, or somatization symptoms when looking at IBS subtypes separately (Table 4). As mentioned above, the analyses of participants from the United Kingdom and Ireland are presented separately in the Supplementary Table 5.

### Functional analysis of variant 5-HT<sub>3</sub>AC receptors

The *HTR3C* SNP encodes the amino acid exchange p.Asn163Lys (p.N163K), and recombinantly expressed 5-HT<sub>3</sub>AC receptors harboring variant 5-HT<sub>3</sub>C subunits that mimic the homozygous minor allele and the heterozygous state presented with increased cell surface expression and enhanced 5-HT maximum response. Radioligand-binding assays revealed higher  $B_{max}$  values of 117.1% ± 4.38% and 111.9% ± 1.79%. Calcium influx assays showed increased 5-HT-induced maximum effects of 137.2% ± 9.0% and 151.9% ± 17.3% for the minor allele 5-HT<sub>3</sub>AC 163K or combined 5-HT<sub>3</sub>AC 163N/5-HT<sub>3</sub>AC 163K receptors compared with the major allele representing 5-HT<sub>3</sub>AC 163N receptors, respectively. The affinity of the specific 5-HT<sub>3</sub> receptor antagonist [<sup>3</sup>H]GR65630, as reflected by the  $K_d$  values, and the potency of 5-HT, as reflected by the  $EC_{50}$  values, did not differ between the receptor variants (Figure 2).

## DISCUSSION

### Main findings

The 5-HT<sub>3</sub> receptors modulate essential functions in the GI tract such as GI motility as well as mood and emotions[19], and *HTR3* SNPs have been associated with depression, anxiety, and IBS[25]. In this study, we showed that: (1) In the dominant model, *HTR3C* c.489C>A was correlated with depressive and anxiety symptoms in IBS; (2) A higher number of minor alleles (*i.e.*, a higher SNP score, which was computed by combining the individual SNP status of *HTR3A* c.-42C>T, *HTR3B* c.386A>C, *HTR3C*

**Table 3 Differences between single-nucleotide polymorphisms in depressive and anxiety symptoms, separately analyzed with ANOVA using the dominant model and the recessive model**

Models	Mental symptoms	SNPs	Total	Sex		IBS subtypes		
				Male	Female	IBS-C	IBS-D	IBS-M
Dominant model	Depressive symptoms	<i>HTR3A</i> c.-42C>T (rs1062613)	2.541	<b>4.149</b> ↑	0286	0.998	0.376	0.694
		<i>HTR3B</i> c.386A>C (rs1176744)	0.067	0.005	0.198	0.282	0.124	0.232
		<i>HTR3C</i> c.489C>A (rs6766410)	<b>7.475</b> ↑	0.672	<b>7.040</b> ↑	0.261	<b>5.670</b> ↑	2.328
		<i>HTR3E</i> c.*76G>A (rs62625044)	0.054	0.013	0.180	0.208	0.461	0.010
	Anxiety symptoms	<i>HTR3A</i> c.-42C>T (rs1062613)	0.511	0.210	0.280	0.604	0.672	0.162
		<i>HTR3B</i> c.386A>C (rs1176744)	0.926	0.406	0.801	0.468	1.369	0.770
		<i>HTR3C</i> c.489C>A (rs6766410)	<b>6.535</b> ↑	0.158	<b>7.550</b> ↑	0.186	<b>13.444</b> ↑	0.045
		<i>HTR3E</i> c.*76G>A (rs62625044)	1.055	0.429	0.853	0.000	0.495	1.109
	Somatization symptoms	<i>HTR3A</i> c.-42C>T (rs1062613)	0.016	0.141	0.106	0.086	0.017	0.203
		<i>HTR3B</i> c.386A>C (rs1176744)	0.217	0.332	0.326	0.407	0.415	2.125
		<i>HTR3C</i> c.489C>A (rs6766410)	0.784	0.035	1.085	0.269	0.000	1.962
		<i>HTR3E</i> c.*76G>A (rs62625044)	0.002	1.554	0.263	0.128	0.729	0.354
Recessive model	Depressive symptoms	<i>HTR3A</i> c.-42C>T (rs1062613)	0.002	0.421	0.132	0.093	1.320	1.064
		<i>HTR3B</i> c.386A>C (rs1176744)	1.118	2.027	0.107	1.741	0.197	0.744
		<i>HTR3C</i> c.489C>A (rs6766410)	0.047	0.821	0.401	2.306	<b>6.190</b> ↑	0.676
		<i>HTR3E</i> c.*76G>A (rs62625044)	0.677	-	0.574	0.541	-	-
	Anxiety symptoms	<i>HTR3A</i> c.-42C>T (rs1062613)	0.479	0.027	0.549	0.057	0.315	0.350
		<i>HTR3B</i> c.386A>C (rs1176744)	0.872	0.081	1.691	0.476	0.361	1.923
		<i>HTR3C</i> c.489C>A (rs6766410)	0.028	2.562	0.344	0.570	3.509	2.093
		<i>HTR3E</i> c.*76G>A (rs62625044)	0.216	-	0.179	0.242	-	-
	Somatization symptoms	<i>HTR3A</i> c.-42C>T (rs1062613)	0.217	0.018	0.257	0.138	0.092	0.431
		<i>HTR3B</i> c.386A>C (rs1176744)	<b>6.482</b> ↑	2.245	3.575	0.142	<b>14.033</b> ↑	0.341
		<i>HTR3C</i> c.489C>A (rs6766410)	0.468	1.813	0.128	<b>4.715</b> ↓	0.002	0.113
		<i>HTR3E</i> c.*76G>A (rs62625044)	0.001	-	0.011	0.000	-	-

F values are shown in the table. Arrows represent the direction of the associations. ↑ dependent variable increases from major to minor alleles; ↓ dependent variable decreases from major to minor alleles. The underlined values were significant. Values in bold were “nominally significant” (*i.e.*, lacking



significance after false discovery rate multiple testing correction). IBS: Irritable bowel syndrome; IBS-C: Constipation-predominant IBS; IBS-D: Diarrhea-predominant IBS; IBS-M: IBS with mixed bowel habits; SNPs: Single-nucleotide polymorphisms.

**Table 4 Association of depressive, anxiety, and somatization symptoms with the single-nucleotide polymorphism score of the four tested polymorphisms**

	Total	Sex		IBS subtypes		
		Male	Female	IBS-C	IBS-D	IBS-M
Depressive symptoms						
<i>F</i> value	<b>7.710</b>	1.336	<b>5.770</b>	1.551	2.159	0.196
<i>P</i> -linear trend value	<b>0.006</b>	0.250	<b>0.017</b>	0.184	0.144	0.659
Anxiety symptoms						
<i>F</i> value	2.150	0.028	2.514	1.372	2.400	1.412
<i>P</i> -linear trend value	0.143	0.866	0.114	0.245	0.123	0.236
Somatization symptoms						
<i>F</i> value	1.15	0.354	1.028	0.716	2.718	0.628
<i>P</i> -linear trend value	0.283	0.553	0.311	0.614	0.102	0.429

Values in bold were “nominally significant” (*i.e.*, lacking significance after false discovery rate multiple testing correction). IBS: Irritable bowel syndrome; IBS-C: Constipation-predominant IBS; IBS-D: Diarrhea-predominant IBS; IBS-M: IBS with mixed bowel habits.

*c.489C>A*, and *HTR3E c.\*76G>A*) was linked to more severe depressive symptoms in IBS; and (3) The potential relevance of the *HTR3C* SNP was corroborated in functional assays showing changes in the expression level of 5-HT<sub>3</sub>AC variant receptors. These findings are discussed in more detail below.

### Sample characteristics

Participants with IBS were more frequently female than male, in line with previous findings[48,49] that IBS is more prevalent in young and middle-aged females. Most participants with IBS were only mildly affected by depression and anxiety symptoms. Of note, German participants only visited the Specialty Clinic for Functional GI Disorders at Heidelberg University Hospital after a long history of dealing with IBS[31]; therefore, these participants reported more severe depressive symptoms. However, causal relationships between IBS symptoms, depression, and anxiety are still controversial.


The investigated SNPs rs1062613, rs1176744, rs6766410, and rs56109847 were in accordance with HWE. There was no population stratification, and the sample was representative and excluded genotyping errors. Although participants were recruited from various centers in different countries, there were no obvious selective differences.

### Connections between HTR3 SNPs and mental symptoms

***HTR3A c.-42C>T (rs1062613)***: Depressive symptoms were “nominally significantly” more severe with increasing numbers of minor *HTR3A c.-42C>T* alleles in male participants according to the dominant model. This SNP has been associated with bipolar affective disorder[50], IBS symptom severity, amygdaloid activity[29,51], early life trauma[52], altered emotional networks in the human brain, and the onset of depression[53]. However, these studies only included single sex participants and did not include subgroup analyses.

***HTR3B c.386A>C (rs1176744)***: Somatization symptoms worsened significantly with increasing numbers of minor *HTR3B c.386A>C* alleles in the dominant model. The *HTR3B* variant p.Tyr129Ser (rs1176744) has been associated with bipolar affective disorder in males and with major depression in females as well as with pain catastrophizing, a coping style characterized by excessively negative thoughts and emotions related to pain[30,54-56]. This discrepancy may be due to an enhancement or weakening of this association by polymorphic interactions in the serotonin pathways[56].

***HTR3C c.489C>A (rs6766410)***: Depressive and anxiety symptoms worsened significantly with increasing numbers of minor *HTR3C c.489C>A* alleles in the dominant model. This effect seemed to be driven by female sex and IBS-D. *HTR3C c.489C>A* was previously associated with IBS-D in female patients[57], but the proportion of male patients was small in this study, which may limit the applicability of these findings. In the recessive model, depressive and anxiety symptoms “nominally



DOI: 10.3748/wjg.v28.i21.2334 Copyright ©The Author(s) 2022.

**Figure 2** Comparative analysis of 5-HT<sub>3</sub>AC 163N (major allele homozygous), 5-HT<sub>3</sub>AC 163K (minor allele homozygous), and 5-HT<sub>3</sub>AC 163K/163N (heterozygous) receptors. A: Radioligand-binding studies Saturation experiments were performed in membranes of HEK293 cells transiently expressing different 5-HT<sub>3</sub> subunit combinations in triplicate with six increasing concentrations of [<sup>3</sup>H]GR65630 (0.02-1.5 nmol/L); K<sub>d</sub> values were 0.07 ± 0.01 for 5-HT<sub>3</sub>AC 163N; 0.08 ± 0.01 for 5-HT<sub>3</sub>AC 163K, and 0.07 ± 0.01 for 5-HT<sub>3</sub>AC 163K/163N. *n* = 6 experiments; B: Concentration response curves were assessed in a calcium influx assay (aequorin assay) in HEK293 cells transiently transfected with different 5-HT<sub>3</sub> subunit combinations in quadruplicate with seven increasing concentrations of 5-HT. pEC<sub>50</sub> values were as follows: 68 ± 0.03 for 5-HT<sub>3</sub>AC 163N and 5.66 ± 0.02 for 5-HT<sub>3</sub>AC 163K; C: Respective maximal calcium influx values (E<sub>max</sub>) evoked by 5-HT (10 μmol/L). Data are expressed as percentages of the E<sub>max</sub> of the heteromeric 5-HT<sub>3</sub>AC 163N receptor (% of control), *n* = 8 experiments. Bars represent mean ± SE. \**P* < 0.01 from ANOVA followed by Dunnett's post-test or unpaired Student's test for comparison of only two groups.

significantly" worsened with increasing numbers of minor alleles of *HTR3C* c.489C>A in Irish participants. However, these results should be interpreted with caution because the Irish sample size was low. As far as we are aware, *HTR3C* c.489C>A has not been analyzed in individuals with affective disorders before.

***HTR3E* c.\*76G>A (rs56109847):** *HTR3E* is restrictedly and robustly expressed in the GI tract[58,59], suggesting that it plays a special role in 5-HT<sub>3</sub> receptor function in the gut. In this study, we did not find a relationship between functional polymorphisms of *HTR3E* and depressive and anxiety symptoms in IBS patients. This may be attributed to a floor effect because depressive and anxiety symptoms were minimal to mild in our sample[60].

#### The SNP score and its impact on depressive symptoms

A single gene variant is not sufficient to explain all symptoms shaping the clinical phenotype of a complex disorder like IBS[61]. By computing SNP scores based on the number of minor alleles of rs1062613, rs1176744, rs6766410, and rs56109847, our study revealed that an increasing number of minor alleles is linked to increasing severity of depressive symptoms. However, there was no obvious association between an increasing number of minor alleles and the severity of anxiety or somatization symptoms. Stratification for sex revealed a correlation between increasing numbers of minor alleles and worsening depressive symptoms in female participants.

#### Functional properties of variant 5-HT<sub>3</sub>AC receptors

*HTR3* genes encode different 5-HT<sub>3</sub> subunits to make up heteromeric receptors. The 5-HT<sub>3</sub>A subunits play a major role in these receptors because they can form functional receptors on their own. The other

subunits can only form functional receptors with 5-HT<sub>3A</sub> and seem to modulate the function and properties of the receptors[62]. How these native receptors might contribute to the pathogenesis of IBS, particularly regarding co-expression patterns of *HTR3*, has not been established yet. The *HTR3A* and *HTR3E* variants reside within untranslated regions and the respective SNPs correlate with increased expression levels, whereas the *HTR3B* variant changes the channel properties[25]. To gain insight into the pathophysiological relevance of the associated *HTR3C* variant c.489C>A (rs6766410), we characterized the pharmacological and functional properties of those 5-HT<sub>3AC</sub> receptors that altered the 5-HT-mediated maximum response and expression of variant 5-HT<sub>3AC</sub> receptors. However, how structural modifications in these receptors affect their function *in vivo* and how they modulate the serotonergic system to influence mood, emotional processing, and the manifestation of IBS and comorbid conditions remains to be determined.

### Limitations and strengths

Our study has some limitations. First, different instruments were used by different centers to assess phenotypic features. To correct for this, scale scores were converted into z standard scores. However, given that the participants reported no severe psychosomatic symptoms, the discovery chances might be limited. Second, there is no sufficient evidence to show the relationship between risk alleles and respective major/minor alleles as patients and healthy controls were not compared in this study. Similarly, the relative strength of the cumulative effect represented by the SNP score was also affected to a certain extent. Third, our participants were all Caucasian, so the results may not apply to other ethnic groups.

Despite these limitations, our study has some strengths. First, this was a multicenter study so had a large sample size. Large, well-characterized samples like ours are necessary to identify molecular causes of IBS and comorbid conditions[12]. Second, this study investigated the association between polymorphisms in *HTR3* genes and comorbid psychosomatic symptoms for the first time. We conducted population stratification tests to ensure that the included populations were comparable. We also performed stratified analyses of sex and IBS subtypes and a more stringent multiple testing correction by FDR. Third, SNP scores have higher power and are better suited to testing multiple instead of single variants. This is useful because the pathogenesis of IBS is complex with multiple factors contributing to the manifestation of various subtypes. Also, individual genes may only play a minor role[12].

### Clinical implications and further research

IBS is a complex condition. The continuous improvement of the allelic variation database for *HTR3*[25] and deep phenotyping combined with gene information (also in other datasets) may help to identify disease subgroups accurately and consistently, thereby facilitating future treatment[33,63]. This will be an important step towards standardization and unification of IBS genetic research strategies.

## CONCLUSION

Our results provide the first evidence that the accumulation of *HTR3* SNPs (reflected by the SNP score computed by *HTR3A* c.-42C>T, *HTR3B* c.386A>C, *HTR3C* c.489C>A, and *HTR3E* c.\*76G>A) may play a role in the pathophysiology of depressive and anxiety symptoms in IBS. This study has revealed that depressive and anxiety symptoms significantly worsened from the major to the minor allele of *HTR3C* c.489C>A in the dominant model and an increasing number of minor alleles are linked to more severe depressive symptoms in IBS.

## ARTICLE HIGHLIGHTS

### Research background

Over the past decades, genetic evidence on the key players within the serotonergic system including the serotonin type 3 (5-HT<sub>3</sub>) receptor subunit genes (*HTR3*) accumulated showing association with irritable bowel syndrome (IBS) as well as mental illnesses. However, it has never been explored whether associations of the single-nucleotide polymorphisms (SNPs) of *HTR3* genes to depressive and anxiety symptoms can be replicated within IBS.

### Research motivation

In order to address this knowledge gap, This multicenter observational study focused on a large IBS patient cohort comprising 768 participants from centers in Germany, Sweden, the United States, the United Kingdom, and Ireland.

**Research objectives**

The objectives are: (1) To explore the associations between functional *HTR3* polymorphisms and psychosomatic burden within an IBS population; (2) To investigate the impact of the *HTR3* SNP score on psychosomatic burden, based on our hypothesis that the observed number of minor alleles was associated with specific mental characteristics in IBS patients; and (3) To perform a functional analysis of variant 5-HT<sub>3</sub>AC receptors.

**Research methods**

In this retrospective study, 623 participants with IBS were recruited from five specialty centers in Germany, Sweden, the United States, the United Kingdom, and Ireland. Depressive, anxiety, and somatization symptoms and sociodemographic characteristics were collected. Four functional SNPs – *HTR3A* c.-42C>T, *HTR3B* c.386A>C, *HTR3C* c.489C>A, and *HTR3E* c.\*76G>A – were genotyped and analyzed using the dominant and recessive models. We also performed separate analyses for sex and IBS subtypes. SNP scores were calculated as the number of minor alleles of the SNPs above. The impact of *HTR3C* c.489C>A was tested by radioligand-binding and calcium influx assays.

**Research results**

Bringing together high quality data as well as methodological expertise, our results show that: (1) In the dominant model, *HTR3C* c.489C>A was correlated with depressive and anxiety symptoms in IBS; (2) A higher number of minor alleles (*i.e.*, the higher the SNP score, which was computed by combining the individual SNP status of *HTR3A* c.-42C>T, *HTR3B* c.386A>C, *HTR3C* c.489C>A, and *HTR3E* c.\*76G>A) was linked to more severe depressive symptoms in IBS; and (3) The potential relevance of the *HTR3C* SNP was corroborated in functional assays showing changes in the expression level of 5-HT<sub>3</sub>AC variant receptors.

**Research conclusions**

Our results provide the first evidence that the accumulation of *HTR3* SNPs (reflected by the SNP score computed by *HTR3A* c.-42C>T, *HTR3B* c.386A>C, *HTR3C* c.489C>A, and *HTR3E* c.\*76G>A) may play a role in the pathophysiology of depressive and anxiety symptoms in IBS.

**Research perspectives**

We are confident that these results are of interest to your readership, as they contribute substantially to update current knowledge regarding the role of accumulation of *HTR3* SNPs in depressive and anxiety symptoms in IBS patients. In turn, our data will contribute towards standardization and harmonization of genetic research strategies in IBS.

---

**ACKNOWLEDGEMENTS**

We would like to thank all patients for their participation in this study and the supporting staff at each site. We acknowledge the kind support of Bartram CR and Hinderhofer K. We would also thank Startt B for proofreading and Bacon C for editing the manuscript. This manuscript results in part from collaboration and network activities promoted under the frame of the international network GENIEUR (Genes in Irritable Bowel Syndrome Research Network Europe), which has been funded by the COST program (BM1106, [www.GENIEUR.eu](http://www.GENIEUR.eu)) and is currently supported by the European Society of Neurogastroenterology and Motility (ESNM, [www.ESNM.eu](http://www.ESNM.eu)).

---

**FOOTNOTES**

**Author contributions:** Mönnikes H, Keller J, Walstab J and Wahl V performed the experiments; Dong Y, Berens S, Schaefer R, Clevers E and Walstab J carried out data analyses; Berens S, Engel F, Gauss A, Herzog W, Spiller R, Clarke G, Dinan TG, Quigley EM, Sayuk G, Simrén M, Tesarz J, Sayuk G and IBS-Net Germany characterized and enrolled the patients; Dong Y, Berens S, and Schaefer R drafted the manuscript; all authors contributed to discussing and editing of the manuscript; Niesler B, Schaefer R and van Oudenhove L designed and supervised the study and revised and finalized the manuscript; Berens S and Dong Y equally contributed to the paper; Schaefer R and Niesler B shared last authorship.

**Institutional review board statement:** The study was reviewed and approved by the Ethical Committee, Medical Faculty of the Heidelberg University Hospital (approval No. S067/2010).

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** APC Microbiome Ireland has conducted studies in collaboration with several

companies, including GSK, Pfizer, Cremo, Santory, Wyeth, Mead Johnson, Nutricia, 4D Pharma, and DuPont. Dinan TG has been an invited speaker at meetings organized by Servier, Lundbeck, Janssen, and AstraZeneca and has received research funding from Mead Johnson, Cremo, Santory Wellness, Nutricia, and 4D Pharma. Clarke G has been an invited speaker at meetings organized by Janssen and is receipt of research funding from Pharmavite. The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this report.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** Germany

**ORCID number:** Sabrina Berens 0000-0001-8585-5304; Yuanjun Dong 0000-0002-7817-767X; Nikola Fritz 0000-0003-2662-4340; Jutta Walstab 0000-0001-9546-2205; Mauro D'Amato 0000-0003-2743-5197; Tenghao Zheng 0000-0003-1587-7481; Verena Wahl 0000-0001-9887-5873; Felix Boekstegers 0000-0002-0587-7624; Justo Lorenzo Bermejo 0000-0002-6568-5333; Cristina Martinez 0000-0002-9368-1356; Stefanie Schmitteckert 0000-0001-9555-2614; Egbert Clevers 0000-0003-1931-4926; Felicitas Engel 0000-0002-9300-5681; Annika Gauss 0000-0001-8661-449X; Wolfgang Herzog 0000-0003-2778-4135; Robin Spiller 0000-0001-6371-4500; Miriam Goebel-Stengel 0000-0003-0995-3062; Hubert Mönnikes 0000-0002-7447-6373; Viola Andresen 0000-0002-3695-3327; Frieling Thomas 0000-0001-8270-1975; Jutta Keller 0000-0002-5884-1115; Christian Pehl 0000-0002-0205-3582; Christoph Stein-Thöringer 0000-0002-8020-6986; Gerard Clarke 0000-0001-9771-3979; Timothy G Dinan 0000-0002-2316-7220; Eamonn M Quigley 0000-0003-4151-7180; Gregory Sayuk 0000-0003-1586-199X; Magnus Simrén 0000-0002-1155-1313; Jonas Tesarz 0000-0003-3268-7778; Gudrun Rappold 0000-0002-3126-1508; Lukas van Oudenhove 0000-0002-6540-3113; Rainer Schaefer 0000-0002-3077-7289; Beate Niesler 0000-0001-7881-6112.

**S-Editor:** Gao CC

**L-Editor:** A

**P-Editor:** Gao CC

## REFERENCES

- 1 **Layer P**, Andresen V, Pehl C, Allescher H, Bischoff SC, Classen M, Enck P, Frieling T, Haag S, Holtmann G, Karaus M, Kathemann S, Keller J, Kuhlbusch-Zicklam R, Kruijs W, Langhorst J, Matthes H, Mönnikes H, Müller-Lissner S, Musial F, Otto B, Rosenberger C, Schemann M, van der Voort I, Dathe K, Preiss JC; Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten; Deutschen Gesellschaft für Neurogastroenterologie und Motilität. [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. *Z Gastroenterol* 2011; **49**: 237-293 [PMID: 21287438 DOI: 10.1055/s-0029-1245976]
- 2 **Dong Y**, Baumeister D, Berens S, Eich W, Tesarz J. Stressful Life Events Moderate the Relationship Between Changes in Symptom Severity and Health-related Quality of Life in Patients With Irritable Bowel Syndrome. *J Clin Gastroenterol* 2020; **54**: 445-451 [PMID: 31503051 DOI: 10.1097/MCG.0000000000001261]
- 3 **Palsson OS**, Whitehead W, Törnblom H, Sperber AD, Simren M. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. *Gastroenterology* 2020; **158**: 1262-1273.e3 [PMID: 31917991 DOI: 10.1053/j.gastro.2019.12.021]
- 4 **Black CJ**, Yiannakou Y, Houghton LA, Ford AC. Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria. *Clin Gastroenterol Hepatol* 2020; **18**: 392-398.e2 [PMID: 31154027 DOI: 10.1016/j.cgh.2019.05.037]
- 5 **Mearin F**, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. *Gastroenterology* 2016 [PMID: 27144627 DOI: 10.1053/j.gastro.2016.02.031]
- 6 **Stasi C**, Caserta A, Nisita C, Cortopassi S, Fani B, Salvadori S, Pancetti A, Bertani L, Gambaccini D, de Bortoli N, Dell'Osso L, Blandizzi C, Marchi S, Bellini M. The complex interplay between gastrointestinal and psychiatric symptoms in irritable bowel syndrome: A longitudinal assessment. *J Gastroenterol Hepatol* 2019; **34**: 713-719 [PMID: 29971822 DOI: 10.1111/jgh.14375]
- 7 **Melchior C**, Desprez C, Riachi G, Leroi AM, Déchelotte P, Achamrah N, Ducrotté P, Tavalacci MP, Gourcerol G. Anxiety and Depression Profile Is Associated With Eating Disorders in Patients With Irritable Bowel Syndrome. *Front Psychiatry* 2019; **10**: 928 [PMID: 31969841 DOI: 10.3389/fpsy.2019.00928]
- 8 **Weinberg DS**, Smalley W, Heidelbaugh JJ, Sultan S; American Gastroenterological Association. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. *Gastroenterology* 2014; **147**: 1146-1148 [PMID: 25224526 DOI: 10.1053/j.gastro.2014.09.001]
- 9 **Simpson CA**, Mu A, Haslam N, Schwartz OS, Simmons JG. Feeling down? *J Affect Disord* 2020; **266**: 429-446 [PMID: 32056910 DOI: 10.1016/j.jad.2020.01.124]
- 10 **Gros DF**, Antony MM, McCabe RE, Swinson RP. Frequency and severity of the symptoms of irritable bowel syndrome

- across the anxiety disorders and depression. *J Anxiety Disord* 2009; **23**: 290-296 [PMID: 18819774 DOI: 10.1016/j.janxdis.2008.08.004]
- 11 **Black CJ**, Yiannakou Y, Houghton LA, Shuweihi F, West R, Guthrie E, Ford AC. Anxiety-related factors associated with symptom severity in irritable bowel syndrome. *Neurogastroenterol Motil* 2020; **32**: e13872 [PMID: 32396247 DOI: 10.1111/nmo.13872]
  - 12 **Gazouli M**, Wouters MM, Kapur-Pojski L, Bengtson MB, Friedman E, Nikčević G, Demetriou CA, Mulak A, Santos J, Niesler B. Lessons learned--resolving the enigma of genetic factors in IBS. *Nat Rev Gastroenterol Hepatol* 2016; **13**: 77-87 [PMID: 26726033 DOI: 10.1038/nrgastro.2015.206]
  - 13 **Zhang WX**, Zhang Y, Qin G, Li KM, Wei W, Li SY, Yao SK. Altered profiles of fecal metabolites correlate with visceral hypersensitivity and may contribute to symptom severity of diarrhea-predominant irritable bowel syndrome. *World J Gastroenterol* 2019; **25**: 6416-6429 [PMID: 31798278 DOI: 10.3748/wjg.v25.i43.6416]
  - 14 **Hausteiner-Wiehle C**, Henningsen P. Irritable bowel syndrome: relations with functional, mental, and somatoform disorders. *World J Gastroenterol* 2014; **20**: 6024-6030 [PMID: 24876725 DOI: 10.3748/wjg.v20.i20.6024]
  - 15 **Enck P**, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley EM, Rajilić-Stojanović M, Schemann M, Schwille-Kiuntke J, Simren M, Zipfel S, Spiller RC. Irritable bowel syndrome. *Nat Rev Dis Primers* 2016; **2**: 16014 [PMID: 27159638 DOI: 10.1038/nrdp.2016.14]
  - 16 **Whitaker-Azmitia PM**. Serotonin and brain development: role in human developmental diseases. *Brain Res Bull* 2001; **56**: 479-485 [PMID: 11750793 DOI: 10.1016/s0361-9230(01)00615-3]
  - 17 **Painsipp E**, Shahbazian A, Holzer P. Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats. *Br J Pharmacol* 2009; **158**: 1210-1226 [PMID: 19785647 DOI: 10.1111/j.1476-5381.2009.00392.x]
  - 18 **Trump D**. Commentary on: "Ipilimumab vs placebo after radiotherapy with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial." Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA, Electronic address: kwon.eugene@mayo.edu; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; Institut Gustave Roussy, University of Paris-Sud, Villejuif, France; Institut Gustave Roussy, Villejuif, France; VU University Medical Centre, Amsterdam, Netherlands; Vienna General Hospital, Medical University Vienna, Vienna, Austria; Institut Bergonié, Bordeaux, France; CHU Caremeau, Nimes, France; Centro Médico Austral, Buenos Aires, Argentina; Centre Jean Perrin, Clermont-Ferrand, France; St John of God Hospital, Subiaco, WA, Australia; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Hospital de Caridade de Ijuí, Ijuí, Brazil; Nottingham University Hospital, Nottingham, UK; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; Hospital Británico de Buenos Aires, Buenos Aires, Argentina; Herlev Hospital, Herlev, Denmark; Odense University Hospital, Odense, Denmark; University of Texas MD Anderson Cancer Center, Houston,. *Urol Oncol* 2016; **34**: 249-250 [PMID: 25907621 DOI: 10.1016/j.urolonc.2015.03.013]
  - 19 **Walstab J**, Rappold G, Niesler B. 5-HT(3) receptors: role in disease and target of drugs. *Pharmacol Ther* 2010; **128**: 146-169 [PMID: 20621123 DOI: 10.1016/j.pharmthera.2010.07.001]
  - 20 **Fukudo S**, Ida M, Akiho H, Nakashima Y, Matsueda K. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. *Clin Gastroenterol Hepatol* 2014; **12**: 953-9.e4 [PMID: 24315882 DOI: 10.1016/j.cgh.2013.11.024]
  - 21 **Garsed K**, Chernova J, Hastings M, Lam C, Marciani L, Singh G, Henry A, Hall I, Whorwell P, Spiller R. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. *Gut* 2014; **63**: 1617-1625 [PMID: 24334242 DOI: 10.1136/gutjnl-2013-305989]
  - 22 **Spiller RC**. Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome. *Curr Opin Pharmacol* 2011; **11**: 68-74 [PMID: 21398180 DOI: 10.1016/j.coph.2011.02.005]
  - 23 **Grzesiak M**, Beszlej JA, Waszczuk E, Szechiński M, Szewczuk-Bogusławska M, Frydecka D, Dobosz T, Jonkisz A, Lebioda A, Małodobra M, Mulak A. Serotonin-Related Gene Variants in Patients with Irritable Bowel Syndrome and Depressive or Anxiety Disorders. *Gastroenterol Res Pract* 2017; **2017**: 4290430 [PMID: 28951738 DOI: 10.1155/2017/4290430]
  - 24 **Niesler B**, Walstab J, Combrink S, Möller D, Kapeller J, Rietdorf J, Bönisch H, Göthert M, Rappold G, Brüß M. Characterization of the novel human serotonin receptor subunits 5-HT3C, 5-HT3D, and 5-HT3E. *Mol Pharmacol* 2007; **72**: 8-17 [PMID: 17392525 DOI: 10.1124/mol.106.032144]
  - 25 **Celli J**, Rappold G, Niesler B. The Human Serotonin Type 3 Receptor Gene (HTR3A-E) Allelic Variant Database. *Hum Mutat* 2017; **38**: 137-147 [PMID: 27763704 DOI: 10.1002/humu.23136]
  - 26 **Guan T**, Li T, Cai W, Huang D, Ouyang P, Wang Y, Chen H, Wu K, Ma X. HTR3A and HTR3E gene polymorphisms and diarrhea predominant irritable bowel syndrome risk: evidence from a meta-analysis. *Oncotarget* 2017; **8**: 100459-100468 [PMID: 29245992 DOI: 10.18632/oncotarget.19682]
  - 27 **Melke J**, Westberg L, Nilsson S, Landen M, Soderstrom H, Baghaei F, Rosmond R, Holm G, Björntorp P, Nilsson LG, Adolfsson R, Eriksson E. A polymorphism in the serotonin receptor 3A (HTR3A) gene and its association with harm avoidance in women. *Arch Gen Psychiatry* 2003; **60**: 1017-1023 [PMID: 14557147 DOI: 10.1001/archpsyc.60.10.1017]
  - 28 **Niesler B**, Weiss B, Fischer C, Nöthen MM, Propping P, Bondy B, Rietschel M, Maier W, Albus M, Franzek E, Rappold GA. Serotonin receptor gene HTR3A variants in schizophrenic and bipolar affective patients. *Pharmacogenetics* 2001; **11**: 21-27 [PMID: 11207027 DOI: 10.1097/00008571-200102000-00003]
  - 29 **Kilpatrick LA**, Labus JS, Coveleskie K, Hammer C, Rappold G, Tillisch K, Bueller JA, Suyenobu B, Jarcho JM, McRoberts JA, Niesler B, Mayer EA. The HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in

- patients with irritable bowel syndrome. *Gastroenterology* 2011; **140**: 1943-1951 [PMID: 21420406 DOI: 10.1053/j.gastro.2011.03.011]
- 30 **Yamada K**, Hattori E, Iwayama Y, Ohnishi T, Ohba H, Toyota T, Takao H, Minabe Y, Nakatani N, Higuchi T, Detera-Wadleigh SD, Yoshikawa T. Distinguishable haplotype blocks in the HTR3A and HTR3B region in the Japanese reveal evidence of association of HTR3B with female major depression. *Biol Psychiatry* 2006; **60**: 192-201 [PMID: 16487942 DOI: 10.1016/j.biopsych.2005.11.008]
- 31 **Berens S**, Kraus F, Gauss A, Tesarz J, Herzog W, Niesler B, Stroe-Kunold E, Schaefer R. A Specialty Clinic for Functional Gastrointestinal Disorders in Tertiary Care: Concept and Patient Population. *Clin Gastroenterol Hepatol* 2017; **15**: 1127-1129 [PMID: 28300691 DOI: 10.1016/j.cgh.2017.02.039]
- 32 **Kapeller J**, Houghton LA, Mönnikes H, Walstab J, Möller D, Bönisch H, Burwinkel B, Autschbach F, Funke B, Lasitschka F, Gassler N, Fischer C, Whorwell PJ, Atkinson W, Fell C, Büchner KJ, Schmidtmann M, van der Voort I, Wissler AS, Berg T, Rappold G, Niesler B. First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. *Hum Mol Genet* 2008; **17**: 2967-2977 [PMID: 18614545 DOI: 10.1093/hmg/ddn195]
- 33 **Boeckxstaens GE**, Drug V, Dumitrascu D, Farmer AD, Hammer J, Hausken T, Niesler B, Pohl D, Pojskic L, Polster A, Simren M, Goebel-Stengel M, Van Oudenhove L, Vassallo M, Wensaas KA, Aziz Q, Houghton LA; COST Action BM1106 GENIEUR members. Phenotyping of subjects for large scale studies on patients with IBS. *Neurogastroenterol Motil* 2016; **28**: 1134-1147 [PMID: 27319981 DOI: 10.1111/nmo.12886]
- 34 **Dong Y**, Baumeister D, Berens S, Eich W, Tesarz J. High Rates of Non-Response Across Treatment Attempts in Chronic Irritable Bowel Syndrome: Results From a Follow-Up Study in Tertiary Care. *Front Psychiatry* 2019; **10**: 714 [PMID: 31681031 DOI: 10.3389/fpsy.2019.00714]
- 35 **Drossman DA**. The functional gastrointestinal disorders and the Rome III process. *Gastroenterology* 2006; **130**: 1377-1390 [PMID: 16678553 DOI: 10.1053/j.gastro.2006.03.008]
- 36 **Kroenke K**, Spitzer RL. The PHQ-9: A new depression diagnostic and severity measure. *Psychiatr Ann* 2002; **32**: 509-515 [DOI: 10.3928/0048-5713-20020901-06]
- 37 **Berens S**, Schaefer R, Baumeister D, Gauss A, Eich W, Tesarz J. Does symptom activity explain psychological differences in patients with irritable bowel syndrome and inflammatory bowel disease? *J Psychosom Res* 2019; **126**: 109836 [PMID: 31627144 DOI: 10.1016/j.jpsychores.2019.109836]
- 38 **Montazeri A**, Vahdaninia M, Ebrahimi M, Jarvandi S. The Hospital Anxiety and Depression Scale (HADS): translation and validation study of the Iranian version. *Health Qual Life Outcomes* 2003; **1**: 14 [PMID: 12816545 DOI: 10.1186/1477-7525-1-14]
- 39 **Wong KM**, Mak ADP, Yuen SY, Leung ONW, Ma DY, Chan Y, Cheong PK, Lui R, Wong SH, Wu JC. Nature and specificity of altered cognitive functioning in IBS. *Neurogastroenterol Motil* 2019; **31**: e13696 [PMID: 31389109 DOI: 10.1111/nmo.13696]
- 40 **Spitzer RL**, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006; **166**: 1092-1097 [PMID: 16717171 DOI: 10.1001/archinte.166.10.1092]
- 41 **Julian LJ**. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). *Arthritis Care Res (Hoboken)* 2011; **63** Suppl 11: S467-S472 [PMID: 22588767 DOI: 10.1002/acr.20561]
- 42 **Kroenke K**, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. *Psychosom Med* 2002; **64**: 258-266 [PMID: 11914441 DOI: 10.1097/00006842-200203000-00008]
- 43 **Shi YY**, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. *Cell Res* 2005; **15**: 97-98 [PMID: 15740637 DOI: 10.1038/sj.cr.7290272]
- 44 **Nelson SC**, Romm JM, Doheny KF, Pugh EW, Laurie CC. Imputation-based genomic coverage assessments of current genotyping arrays: Illumina HumanCore, OmniExpress, Multi-Ethnic global array and sub-arrays, Global Screening Array, Omni2.5M, Omni5M, and Affymetrix UK Biobank. 2017 Preprint. Available from: bioRxiv:150219 [DOI: 10.1101/150219]
- 45 **Bonfiglio F**, Henström M, Nag A, Hadizadeh F, Zheng T, Cenit MC, Tigchelaar E, Williams F, Reznichenko A, Ek WE, Rivera NV, Homuth G, Aghdassi AA, Kacprowski T, Männikkö M, Karhunen V, Bujanda L, Rafter J, Wijmenga C, Ronkainen J, Hysi P, Zhernakova A, D'Amato M. A GWAS meta-analysis from 5 population-based cohorts implicates ion channel genes in the pathogenesis of irritable bowel syndrome. *Neurogastroenterol Motil* 2018; **30**: e13358 [PMID: 29673008 DOI: 10.1111/nmo.13358]
- 46 **Marees AT**, de Kluiver H, Stringer S, Vorspan F, Curis E, Marie-Claire C, Derks EM. A tutorial on conducting genome-wide association studies: Quality control and statistical analysis. *Int J Methods Psychiatr Res* 2018; **27**: e1608 [PMID: 29484742 DOI: 10.1002/mpr.1608]
- 47 **Benjamini Y**, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. *J R Stat Soc Series B Stat Methodol* 1995; **57**: 289-300 [DOI: 10.1111/j.2517-6161.1995.tb02031.x]
- 48 **Zhu L**, Huang D, Shi L, Liang L, Xu T, Chang M, Chen W, Wu D, Zhang F, Fang X. Intestinal symptoms and psychological factors jointly affect quality of life of patients with irritable bowel syndrome with diarrhea. *Health Qual Life Outcomes* 2015; **13**: 49 [PMID: 25925746 DOI: 10.1186/s12955-015-0243-3]
- 49 **Simrén M**, Ringström G, Björnsson ES, Abrahamsson H. Treatment with hypnotherapy reduces the sensory and motor component of the gastrocolonic response in irritable bowel syndrome. *Psychosom Med* 2004; **66**: 233-238 [PMID: 15039508 DOI: 10.1097/01.psy.0000116964.76529.6e]
- 50 **Niesler B**, Flohr T, Nöthen MM, Fischer C, Rietschel M, Franzeck E, Albus M, Propping P, Rappold GA. Association between the 5' UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. *Pharmacogenetics* 2001; **11**: 471-475 [PMID: 11505217 DOI: 10.1097/00008571-200108000-00002]
- 51 **Iidaka T**, Ozaki N, Matsumoto A, Nogawa J, Kinoshita Y, Suzuki T, Iwata N, Yamamoto Y, Okada T, Sadato N. A variant C178T in the regulatory region of the serotonin receptor gene HTR3A modulates neural activation in the human amygdala. *J Neurosci* 2005; **25**: 6460-6466 [PMID: 16000636 DOI: 10.1523/JNEUROSCI.5261-04.2005]

- 52 **Gatt JM**, Williams LM, Schofield PR, Dobson-Stone C, Paul RH, Grieve SM, Clark CR, Gordon E, Nemeroff CB. Impact of the HTR3A gene with early life trauma on emotional brain networks and depressed mood. *Depress Anxiety* 2010; **27**: 752-759 [PMID: 20694966 DOI: 10.1002/da.20726]
- 53 **Gatt JM**, Nemeroff CB, Schofield PR, Paul RH, Clark CR, Gordon E, Williams LM. Early life stress combined with serotonin 3A receptor and brain-derived neurotrophic factor valine 66 to methionine genotypes impacts emotional brain and arousal correlates of risk for depression. *Biol Psychiatry* 2010; **68**: 818-824 [PMID: 20728877 DOI: 10.1016/j.biopsych.2010.06.025]
- 54 **Hammer C**, Cichon S, Mühleisen TW, Haenisch B, Degenhardt F, Mattheisen M, Breuer R, Witt SH, Strohmaier J, Oruc L, Rivas F, Babadjanova G, Grigoriou-Serbanescu M, Hauser J, Röth R, Rappold G, Rietschel M, Nöthen MM, Niesler B. Replication of functional serotonin receptor type 3A and B variants in bipolar affective disorder: a European multicenter study. *Transl Psychiatry* 2012; **2**: e103 [PMID: 22832903 DOI: 10.1038/tp.2012.30]
- 55 **Frank B**, Niesler B, Nöthen MM, Neidt H, Propping P, Bondy B, Rietschel M, Maier W, Albus M, Rappold G. Investigation of the human serotonin receptor gene HTR3B in bipolar affective and schizophrenic patients. *Am J Med Genet B Neuropsychiatr Genet* 2004; **131B**: 1-5 [PMID: 15389765 DOI: 10.1002/ajmg.b.30070]
- 56 **Horjales-Araujo E**, Demontis D, Lund EK, Finnerup NB, Børglum AD, Jensen TS, Svensson P, Vase L. Polymorphism in serotonin receptor 3B is associated with pain catastrophizing. *PLoS One* 2013; **8**: e78889 [PMID: 24244382 DOI: 10.1371/journal.pone.0078889]
- 57 **Kapeller J**, Houghton LA, Walstab J, Boenisch H, Rappold G, Niesler B. 1003 A Coding Variant in the Serotonin Receptor 3C Subunit Is Associated with Diarrhea-Predominant Irritable Bowel Syndrome. *Gastroenterology* 2009; **136**: A-155 [DOI: 10.1016/s0016-5085(09)60701-0]
- 58 **Niesler B**, Frank B, Kapeller J, Rappold GA. Cloning, physical mapping and expression analysis of the human 5-HT<sub>3</sub> serotonin receptor-like genes HTR3C, HTR3D and HTR3E. *Gene* 2003; **310**: 101-111 [PMID: 12801637 DOI: 10.1016/s0378-1119(03)00503-1]
- 59 **Karnovsky AM**, Gotow LF, McKinley DD, Piechan JL, Ruble CL, Mills CJ, Schellin KA, Slightom JL, Fitzgerald LR, Benjamin CW, Roberds SL. A cluster of novel serotonin receptor 3-like genes on human chromosome 3. *Gene* 2003; **319**: 137-148 [PMID: 14597179 DOI: 10.1016/s0378-1119(03)00803-5]
- 60 **Maxwell SE**, Delaney HD. Measurement and Statistics - an Examination of Construct-Validity. *Psychol Bull* 1985; **97**: 85-93 [DOI: 10.1037/0033-2909.97.1.85]
- 61 **Mayer EA**, Labus JS, Tillisch K, Cole SW, Baldi P. Towards a systems view of IBS. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 592-605 [PMID: 26303675 DOI: 10.1038/nrgastro.2015.121]
- 62 **Yaakob NS**, Nguyen DT, Exintaris B, Irving HR. The C and E subunits of the serotonin 5-HT<sub>3</sub> receptor subtly modulate electrical properties of the receptor. *Biomed Pharmacother* 2018; **97**: 1701-1709 [PMID: 29793334 DOI: 10.1016/j.biopha.2017.12.010]
- 63 **Katsnelson A**. Diagnostics: Filling in the missing pieces. *Nature* 2016; **533**: S110-S111 [PMID: 27191489 DOI: 10.1038/533S110a]





Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

